In New Hampshire, the Attorney General's office has announced plans to investigate a number of area pharmaceutical companies after a preliminary review indicated that some companies may have minimized the risk of addiction from long-term use of opioids. The fraudulent marketing could have deceived doctors and patients as well as caused the state to pay unnecessarily for opioid prescriptions. The names of the companies that could be investigated were not released. The state recently became the last in the nation to approve a prescription monitoring program that can track patient prescriptions. "As we work to improve provider training and to develop stronger, more explicit and more up-to-date rules on the prescribing of opioids, this investigation will help us better understand and combat the causes of the heroin and opioid crisis," Gov. Maggie Hassan of New Hampshire said.